- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human immunodeficiency virus (HIV) infection
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Dolutegravir with lamivudine – July 2019
Dolutegravir with Lamivudine: Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg; Dovato®
Last updated
15 November 2019